万泰生物 reported revenue of ¥1.05B for the period ended 2026-06-30, +24.3% year on year. Net income was ¥-0.13B, a -12.6% net margin on a 63.9% gross margin. The largest revenue line is 诊断试剂 at 50% of the total. Free cash flow for the period was ¥0.04B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.05B | +24.3% |
| Gross profit | ¥0.67B | — |
| Operating income | ¥-0.14B | — |
| Net income | ¥-0.13B | — |
| Gross margin | 63.9% | Net margin -12.6% |
| Revenue Q/Q | +0.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 诊断试剂 | ¥0.52B | 49.5% |
| 疫苗 | ¥0.43B | 40.9% |
| 诊断仪器 | ¥0.04B | 3.7% |
| 代理产品 | ¥0.03B | 3.3% |
| 其他(补充) | ¥0.02B | 1.9% |
| 活性原料 | ¥0.01B | 0.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.38B | 36.1% |
| R&D | ¥0.26B | 24.9% |
| SG&A | ¥0.51B | 48.8% |
| Tax & other | ¥-0.01B | -0.5% |
| Item | Amount |
|---|---|
| Total assets | ¥13.71B |
| Total liabilities | ¥1.81B |
| Shareholders' equity | ¥11.90B |
| Equity / assets | 86.8% |
| Operating cash flow | ¥0.15B |
| Capital expenditure | ¥0.11B |
| Free cash flow | ¥0.04B |
| Cash conversion (OCF / net income) | 61% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
豪威集团 ・ 华友钴业 ・ 瑞芯微 ・ 兆易创新 ・ 洛阳钼业 ・ 德业股份 ・ 东鹏饮料 ・ 澜起科技 ・ 中国通号 ・ 中微公司 ・ 传音控股 ・ 海光信息
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies